The PIAS2 (Protein Inhibitor of Activated STAT2) antibody is a crucial tool in studying the PIAS family of proteins, which regulate various cellular processes, including signal transduction, transcriptional regulation, and post-translational modifications. PIAS2 functions as an E3 SUMO ligase, modulating the activity of transcription factors such as STATs, NF-κB, and p53 through SUMOylation. It plays roles in inflammation, immune responses, apoptosis, and DNA repair. The antibody specifically targets PIAS2 isoforms (PIAS2α and PIAS2β) to detect their expression, localization, and interactions in experimental models like Western blotting, immunofluorescence, and immunoprecipitation. Research using PIAS2 antibodies has highlighted its involvement in cancer progression, neurodegenerative diseases, and autoimmune disorders. For instance, dysregulated PIAS2 expression correlates with tumor suppression or promotion, depending on cellular context. Commercially available PIAS2 antibodies are typically developed in hosts like rabbits or mice, validated for specificity using knockout controls or siRNA. Challenges include cross-reactivity with other PIAS family members, necessitating careful validation. Ongoing studies aim to clarify PIAS2's dual roles and therapeutic potential, making its antibody a vital reagent in molecular and pathological research.